n-(4-(2-(dimethylamino)ethoxy)benzyl)-3,4-dimethoxybenzmide has been researched along with domperidone in 2 studies
| Studies (n-(4-(2-(dimethylamino)ethoxy)benzyl)-3,4-dimethoxybenzmide) | Trials (n-(4-(2-(dimethylamino)ethoxy)benzyl)-3,4-dimethoxybenzmide) | Recent Studies (post-2010) (n-(4-(2-(dimethylamino)ethoxy)benzyl)-3,4-dimethoxybenzmide) | Studies (domperidone) | Trials (domperidone) | Recent Studies (post-2010) (domperidone) |
|---|---|---|---|---|---|
| 18 | 0 | 8 | 1,977 | 275 | 468 |
| Protein | Taxonomy | n-(4-(2-(dimethylamino)ethoxy)benzyl)-3,4-dimethoxybenzmide (IC50) | domperidone (IC50) |
|---|---|---|---|
| Solute carrier family 22 member 2 | Homo sapiens (human) | 7.9 | |
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 1.332 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 2.614 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 2.74 | |
| D(2) dopamine receptor | Homo sapiens (human) | 0.0026 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 2.125 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 1.011 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 2.614 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 1.065 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.037 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 1.332 | |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | 3.055 | |
| Histamine H1 receptor | Homo sapiens (human) | 1.344 | |
| Mu-type opioid receptor | Homo sapiens (human) | 4.218 | |
| D(3) dopamine receptor | Homo sapiens (human) | 0.018 | |
| Kappa-type opioid receptor | Homo sapiens (human) | 6.994 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 2.6 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.0052 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 0.1447 | |
| Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | 2.3 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ito, Y; Itoh, Z; Iwanaga, Y; Kato, H; Miyashita, N; Mizutani, F; Morikawa, K | 1 |
| Itoh, Z; Iwanaga, Y; Kondo, Y; Miyashita, N; Mizumoto, A; Morikawa, K | 1 |
2 other study(ies) available for n-(4-(2-(dimethylamino)ethoxy)benzyl)-3,4-dimethoxybenzmide and domperidone
| Article | Year |
|---|---|
Stimulatory effect of N-[4-[2-(dimethylamino)-ethoxy] benzyl]-3,4-dimethoxybenzamide hydrochloride (HSR-803) on normal and delayed gastrointestinal propulsion.
Topics: Acetaminophen; Administration, Oral; Animals; Benzamides; Benzyl Compounds; Cisapride; Dogs; Domperidone; Dopamine; Dyspepsia; Female; Gastric Emptying; Gastrointestinal Motility; Male; Metoclopramide; Mice; Piperidines; Rats; Rats, Inbred Strains; Stimulation, Chemical | 1991 |
A novel water-soluble dopamine-2 antagonist with anticholinesterase activity in gastrointestinal motor activity. Comparison with domperidone and neostigmine.
Topics: Animals; Benzamides; Benzyl Compounds; Cholinesterase Inhibitors; Dogs; Domperidone; Dopamine Antagonists; Female; Gastrointestinal Motility; Male; Muscle Contraction; Muscle, Smooth; Neostigmine | 1990 |